The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy (LEVO-CTEPH)
The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy: a Single-center Pilot Prospective Randomized Placebo-controlled Double-blind Clinical Trial
A single-center pilot prospective randomized placebo-controlled double-blind clinical trial.
Study objective - to investigate the efficacy and safety of levosimendan in patients in the perioperative period following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH).
Research Objectives:
- To assess the impact of levosimendan administration on pulmonary artery pressure during the perioperative period in patients who have undergone pulmonary endarterectomy for CTEPH.
- To evaluate the effect of levosimendan administration on right ventricular function parameters during the perioperative period in patients after pulmonary endarterectomy for CTEPH.
- To determine the influence of levosimendan on the need for inotropic and vasopressor support (VIS) during the perioperative period in patients following pulmonary endarterectomy for CTEPH.
- To examine the effect of levosimendan on the clinical course and complications during the postoperative period in patients after pulmonary endarterectomy for CTEPH.
- To evaluate the cardioprotective effect of levosimendan in patients following pulmonary endarterectomy for CTEPH.
- To assess the impact of levosimendan on in-hospital mortality in patients after pulmonary endarterectomy for CTEPH.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and severe form of pulmonary hypertension resulting from thrombotic obstruction of the pulmonary arteries. It is typically a late complication of acute pulmonary embolism. The incidence of CTEPH has been reported to reach 13 cases per million population per year.
Organized thrombotic masses cause stenosis or obstruction of the pulmonary arteries, leading to increased pulmonary artery pressure and pulmonary vascular resistance. This results in redistribution of pulmonary blood flow, microangiopathy, and remodeling of small-caliber pulmonary vessels. Pulmonary endarterectomy (PEA) is the recommended standard of care for patients with CTEPH and can be curative. In experienced centers, mortality rates are less than 5%.
Residual pulmonary hypertension after PEA, defined as a mean pulmonary artery pressure ≥25 mmHg, occurs in 17-51% of patients. This complication is associated with residual thrombotic material in distal pulmonary arteries and small-vessel disease. Severe pulmonary hypertension causes right ventricular maladaptive remodeling and dysfunction, ultimately leading to right ventricular failure, which is the most important determinant of survival and quality of life. Residual pulmonary hypertension negatively affects long-term survival, with higher mortality associated with mean pulmonary artery pressure ≥36 mmHg and pulmonary vascular resistance ≥416 dyn·s·cm-⁵.
Currently, a multimodal approach to CTEPH is being considered. Surgery addresses the primary component by removing thrombotic masses, but pharmacotherapy is required for the microvascular component and persistently elevated pulmonary artery pressure. Targeted therapies are costly, and their benefit remains unclear. Clinical guidelines currently recommend only symptomatic therapy for patients with residual pulmonary hypertension and right ventricular failure after PEA, and no optimal treatment strategy has been defined for this complication in the early postoperative period.
Rationale for Levosimendan: Levosimendan has shown promising effects in pulmonary hypertension and right ventricular failure. Its mechanism of action involves opening ATP-dependent potassium channels in vascular smooth muscle cells, leading to vasodilation and reduction of both preload and afterload. Additionally, levosimendan binds to cardiac troponin C, increasing myofibril contractility. Previous studies have demonstrated that levosimendan reduces pulmonary artery pressure and pulmonary vascular resistance, improves right ventricular function (including increased TAPSE, ejection fraction, and cardiac output), and suppresses smooth muscle cell proliferation in pulmonary arteries. However, no studies to date have investigated the effect of levosimendan in patients with CTEPH undergoing pulmonary endarterectomy, and the drug has not previously been used in the perioperative management of this patient population.
Study objective is to evaluate the effect of levosimendan on pulmonary artery pressure and right ventricular function in patients undergoing pulmonary endarterectomy for CTEPH.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Gleb Moroz, PhD
- 電話番号:+79833177148
- メール:g_moroz@meshalkin.ru
研究場所
-
-
-
Novosibirsk、ロシア、630055
- 募集
- Meshalkin Research Institute of Pathology of Circulation
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntary signed informed consent to participate in the study
- Scheduled for pulmonary thromboendarterectomy surgery
- Aged ≥18 years
Exclusion Criteria :
- Patient refusal
- Language barrier preventing understanding of the study
- Severe renal failture (creatinine clearance <30 mL/min)
- Severe hepatic insufficiency (Child-Pugh score >9 points)
- Participation in other clinical trials
- History of allergic reaction to levosimendan, Soluvit, or any of their components
- Use of levosimendan within 30 days prior to screening
Discontinuation Criteria (or Withdrawal Criteria):
- Need for extracorporeal membrane oxygenation (ECMO) support during the perioperative period
- Pulmonary hemorrhage during the perioperative period
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Levosimendan
A levosimendan infusion after induction of anesthesia. |
Infusion of levosimendan will be initiated after the induction of anesthesia, discontinued at the onset of patient cooling, and resumed at the time of rewarming at 34°C. The drug will be administered using an infusion pump as a continuous infusion at a rate of 0.1 mcg/kg/min. The duration of the drug infusion will be up to 48 hours. Preoperative management will be conducted according to the patients' primary and concomitant diseases. |
|
プラセボコンパレーター:"Soluvit"
A placebo infusion after induction of anesthesia. |
Patients in the placebo group will receive an equivalent amount of a colored solution of Soluvit.Soluvit (ATC B05XC; a yellow vitamin mixture indistinguishable from the investigational drug, levosimendan). Preoperative management will be conducted according to the patients' primary and concomitant diseases. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean pulmonary artery pressure (mPAP)
時間枠:24 hours at the end of surgery
|
Mean pulmonary artery pressure (mPAP) measured 24 hours after the end of surgery |
24 hours at the end of surgery
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pulmonary Vascular Resistance (PVR)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Pulmonary vascular resistance |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Pulmonary Artery Pulsatility Index (PAPI)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Pulmonary artery pulsatility index. PAPi = (PASP - PADP) / RAP (PASP - PADP): Pulmonary Artery Pulse Pressure. This is the difference between the pressure in the pulmonary artery when the heart contracts (systolic) and relaxes (diastolic). RAP: Right Atrial Pressure. |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Pulmonary Artery Pressure (PAP)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Pulmonary artery pressure |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Arterial Blood Pressure (ABP)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Arterial blood pressure |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Central Venous Pressure (CVP)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Central venous pressure |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Cardiac Index (CI)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Cardiac index |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Systemic Vascular Resistance (SVR)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Systemic vascular resistance |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Right Ventricular Stroke Work Index (RVSWI)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Right ventricular stroke work index |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Pulmonary Capillary Wedge Pressure (PAWP)
時間枠:• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
Pulmonary capillary wedge pressure |
• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
|
|
Ejection fraction
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Ejection fraction (EF) of both the right and left ventricles (LVEF and RVEF) |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Right Ventricular End-Diastolic Volume (RVEDV)
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Right ventricular end diastolic volume |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Right Ventricular systolic pressure (RVSP)
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Right ventricular systolic pressure |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Fractional area change (FAC) of the right ventricle
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Fractional area change (FAC) of the right ventricle |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Tricuspid annular plane systolic excursion (TAPSE)
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Tricuspid annular plane systolic excursion |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Right ventricular free-wall longitudinal strain (RV FW LS)
時間枠:• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
Right ventricular free-wall longitudinal strain |
• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Quantitative troponin I level
時間枠:• before skin incision• 24 hours after the end of surgery• 48 hours after surgery
|
Quantitative concentration of troponin I |
• before skin incision• 24 hours after the end of surgery• 48 hours after surgery
|
|
Vasoactive Inotropic Support
時間枠:• before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
In the perioperative period, the Vasoactive-Inotropic Score (VIS) will be calculated using the following formula: VIS = dobutamine (mcg/kg/min) + dopamine (mcg/kg/min) + (100 × epinephrine (mcg/kg/min) + (100 × norepinephrine (mcg/kg/min)) + (10 × milrinone (mcg/kg/min)) |
• before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
|
|
Residual Pulmonary Hypertension
時間枠:From the end of surgery up to 72 hours postoperatively
|
Number of participants with residual pulmonary hypertension, defined as postoperative mean pulmonary artery pressure (mPAP) > 25 mm Hg, measured by right heart catheterization in the postoperative period (up to 72 hours after surgery). |
From the end of surgery up to 72 hours postoperatively
|
|
Incidence of reperfusion pulmonary edema
時間枠:From the end of surgery up to 72 hours postoperatively
|
Number of participants who develop pulmonary edema within 24 hours following pulmonary endarterectomy (PEA), confirmed by chest X-ray or chest CT and clinical criteria (including dyspnea, hypoxemia, and bilateral infiltrates), characterized by the presence of frothy secretions in the endotracheal tube (ETT), asymmetric opacities on chest X-ray, and an oxygenation index (PaO₂/FiO₂) < 300 mm Hg in the early postoperative period (up to 72 hours) |
From the end of surgery up to 72 hours postoperatively
|
|
Incidence of cardiac arrhythmias
時間枠:30 days
|
Proportion of participants who develop any new-onset cardiac arrhythmia (including atrial fibrillation/flutter, ventricular tachycardia) during the study period, as documented by 12-lead ECG or continuous cardiac monitoring. |
30 days
|
|
Cardiovascular events: myocardial infarction or stroke
時間枠:30 days
|
Number of participants with cardiovascular events, defined as myocardial infarction (MI) or stroke (cerebrovascular accident, CVA), occurring during the postoperative period.Myocardial infarction is defined according to the Fourth Universal Definition of Myocardial Infarction (elevated cardiac troponin with at least one of the following: ischemic symptoms, new ischemic ECG changes, or imaging evidence of new loss of viable myocardium). Stroke is defined as an acute episode of focal or global neurological dysfunction caused by infarction or hemorrhage in the brain, spinal cord, or retina, confirmed by neuroimaging (CT or MRI). |
30 days
|
|
Respiratory Complications: Pneumothorax
時間枠:30 days
|
Number of participants with postoperative pneumothorax, defined as the presence of air in the pleural cavity, confirmed by chest X-ray or chest CT, occurring during the postoperative period. |
30 days
|
|
Neurological Complications: Seizures
時間枠:From enrollment to the end of treatment at 30 days
|
Number of participants with postoperative seizures, defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Diagnosis is based on clinical assessment and, when available, confirmed by electroencephalography (EEG). |
From enrollment to the end of treatment at 30 days
|
|
Renal complications: acute kidney injury (AKI) according to KDIGO criteria
時間枠:30 days
|
Number of participants with postoperative acute kidney injury (AKI), defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, occurring during the early postoperative period (up to 48 hours after surgery). AKI is defined as any of the following: increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours; or increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine output < 0.5 mL/kg/hour for 6 hours. AKI is staged as follows: Stage 1 (serum creatinine 1.5-1.9 times baseline or ≥ 0.3 mg/dL increase, or urine output < 0.5 mL/kg/hour for 6-12 hours), Stage 2 (serum creatinine 2.0-2.9 times baseline, or urine output < 0.5 mL/kg/hour for ≥ 12 hours), and Stage 3 (serum creatinine ≥ 3.0 times baseline, or increase to ≥ 4.0 mg/dL, or initiation of renal replacement therapy, or urine output < 0.3 mL/kg/hour for ≥ 24 hours, or anuria for ≥ 12 hours). |
30 days
|
|
Renal replacement therapy (RRT)
時間枠:From enrollment to the end of treatment at 30 days
|
Number of participants who require renal replacement therapy (RRT) in the early postoperative period |
From enrollment to the end of treatment at 30 days
|
|
Use of inhaled nitric oxide (NO) and/or iloprost
時間枠:30 days
|
Number of participants requiring administration of inhaled nitric oxide (NO) and/or inhaled iloprost in the postoperative period. for the management of residual pulmonary hypertension or right ventricular dysfunction. This includes administration as monotherapy or in combination |
30 days
|
|
Blood transfusion
時間枠:30 days
|
Number of participants requiring perioperative blood transfusion, including packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelet concentrates, or cryoprecipitate, in the postoperative period. Transfusion requirements will be recorded as the number of participants receiving any transfusion. |
30 days
|
|
Inotropic/vasopressor support
時間枠:From the end of surgery up to 72 hours postoperatively
|
Number of participants requiring postoperative inotropic and/or vasopressor support in the early postoperative period |
From the end of surgery up to 72 hours postoperatively
|
|
Duration of mechanical ventilation (MV)
時間枠:30 days
|
Total duration of invasive mechanical ventilation (MV) measured in hours (or days) from the time of intubation in the operating room or ICU until successful extubation. This includes the total time on the ventilator, both in the operating room and in the ICU, and includes any episodes of reintubation. |
30 days
|
|
Duration of ICU stay
時間枠:90 days
|
Total length of stay in the intensive care unit (ICU) measured in days from the time of admission to the ICU after surgery until discharge from the ICU to the general ward. |
90 days
|
|
Duration of hospital stay
時間枠:90 days
|
Total length of hospital stay measured in days |
90 days
|
|
In-hospital mortality
時間枠:90 days
|
yes/no |
90 days
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
- Hansen MS, Andersen A, Nielsen-Kudsk JE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018 Jul-Sep;8(3):2045894018790905. doi: 10.1177/2045894018790905. Epub 2018 Jul 6.
- Kundra TS, Nagaraja PS, Bharathi KS, Kaur P, Manjunatha N. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement. Ann Card Anaesth. 2018 Jul-Sep;21(3):328-332. doi: 10.4103/aca.ACA_19_18.
- Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jais X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29.
- Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011 Mar;141(3):702-10. doi: 10.1016/j.jtcvs.2010.11.024.
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023 Jan 6;61(1):2200879. doi: 10.1183/13993003.00879-2022. Print 2023 Jan. No abstract available.
- Kleber FX, Bollmann T, Borst MM, Costard-Jackle A, Ewert R, Kivikko M, Petterson T, Pohjanjousi P, Sonntag S, Wikstrom G. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009 Jan;49(1):109-15. doi: 10.1177/0091270008325150. Epub 2008 Nov 3. No abstract available.
- Bharathi KS, Pruthi G, Dhananjaya M, Simha PP. The effect of levosimendan on the right ventricular function in patients with right ventricular dysfunction undergoing mitral valve surgery. Ann Card Anaesth. 2023 Jan-Mar;26(1):50-56. doi: 10.4103/aca.aca_179_21.
- Robertson IM, Baryshnikova OK, Li MX, Sykes BD. Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. Biochemistry. 2008 Jul 15;47(28):7485-95. doi: 10.1021/bi800438k. Epub 2008 Jun 21.
- Ali R, Sajjad W, Mushtaq I, Farooqi H, Sohail A, Wazir Khan H, Tabasum P, Haseeb A, Ismail WU. Unlocking the Therapeutic Symphony: A Systematic Review Exploring the Role of Levosimendan in the Management of Heart Failure. Cureus. 2024 Jun 20;16(6):e62799. doi: 10.7759/cureus.62799. eCollection 2024 Jun.
- Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, Treacy C, Ponnaberanam A, Condliffe R, Sheares K, Taboada D, Dunning J, Tsui S, Ng C, Gopalan D, Screaton N, Elliot C, Gibbs S, Howard L, Corris P, Lordan J, Johnson M, Peacock A, MacKenzie-Ross R, Schreiber B, Coghlan G, Dimopoulos K, Wort SJ, Gaine S, Moledina S, Jenkins DP, Pepke-Zaba J. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation. 2016 May 3;133(18):1761-71. doi: 10.1161/CIRCULATIONAHA.115.019470. Epub 2016 Apr 6.
- Ishida K, Kohno H, Matsuura K, Sugiura T, Sanada TJ, Naito A, Shigeta A, Suda R, Sekine A, Masuda M, Sakao S, Tanabe N, Tatsumi K, Matsumiya G. Impact of residual pulmonary hypertension on long-term outcomes after pulmonary endarterectomy in the modern era. Pulm Circ. 2023 Apr 1;13(2):e12215. doi: 10.1002/pul2.12215. eCollection 2023 Apr.
- Llucia-Valldeperas A, de Man FS, Bogaard HJ. Adaptation and Maladaptation of the Right Ventricle in Pulmonary Vascular Diseases. Clin Chest Med. 2021 Mar;42(1):179-194. doi: 10.1016/j.ccm.2020.11.010. Epub 2021 Jan 12.
- Jujo T, Sakao S, Ishibashi-Ueda H, Ishida K, Naito A, Sugiura T, Shigeta A, Tanabe N, Masuda M, Tatsumi K. Evaluation of the Microcirculation in Chronic Thromboembolic Pulmonary Hypertension Patients: The Impact of Pulmonary Arterial Remodeling on Postoperative and Follow-Up Pulmonary Arterial Pressure and Vascular Resistance. PLoS One. 2015 Aug 7;10(8):e0133167. doi: 10.1371/journal.pone.0133167. eCollection 2015.
- Kim NH, D'Armini AM, Delcroix M, Jais X, Jevnikar M, Madani MM, Matsubara H, Palazzini M, Wiedenroth CB, Simonneau G, Jenkins DP. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024 Oct 31;64(4):2401294. doi: 10.1183/13993003.01294-2024. Print 2024 Oct.
- Jenkins D. Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2015 Jun;24(136):263-71. doi: 10.1183/16000617.00000815.
- Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004 Apr;23(4):637-48. doi: 10.1183/09031936.04.00079704.
- Bousseau S, Sobrano Fais R, Gu S, Frump A, Lahm T. Pathophysiology and new advances in pulmonary hypertension. BMJ Med. 2023 Mar 23;2(1):e000137. doi: 10.1136/bmjmed-2022-000137. eCollection 2023.
- Durrington C, Hurdman JA, Elliot CA, Maclean R, Van Veen J, Saccullo G, De-Foneska D, Swift AJ, Smitha R, Hill C, Thomas S, Dwivedi K, Alabed S, Wild JM, Charalampopoulos A, Hameed A, Rothman AMK, Watson L, Hamilton N, Thompson AAR, Condliffe R, Kiely DG. Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. Eur Respir J. 2024 Mar 14;63(3):2300846. doi: 10.1183/13993003.00846-2023. Print 2024 Mar.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 323
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data sharing is not planned as this is a single-center study and institutional regulations do not permit sharing of individual patient data.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。